Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
about
Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer.Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor TherapyAssociations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy.MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
P2860
Q33777302-32BCDB05-5638-47FE-90C7-C9529EB3F120Q34903656-E307B721-C7FC-4FA5-AD18-26D0FC55035FQ35661622-4549594C-B71F-4342-911C-F09A14290620Q36489727-BB4411CC-D354-415E-B73A-19B2BBB1559BQ36693164-58866694-47D0-4D86-8009-E00609EC33B3Q36728379-5430668F-5E18-48A4-9AAA-47F57AD16C2AQ37662607-64EBEC64-0A0B-4B51-83E9-A57B102D5E98Q38737784-29E0CBC1-6E85-4E78-9ED0-F428D9AD2B91Q38739248-57D6AEEB-C00D-409F-94AF-656045326C1DQ38851505-5FAB1E19-F9E7-4F54-AF7D-7D63B73B17C8Q38956073-C2E6CF9D-A1E6-49EE-99DB-887D20BD825AQ42367688-6979910A-1720-44F0-A576-687DA34689C9Q47312891-586DD59D-0841-481C-A2FF-61383C65A5FBQ47560871-3CB4569E-2807-4E9C-B8B7-50CC2EFE52ECQ47577378-12A6A206-8ADB-4D13-A29E-7E567CE65A57Q48165319-65931DDF-FE0F-4053-AFCF-66719FB99799Q51072176-B950F3A8-8AD2-4609-820B-323AEA3EA6C6
P2860
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Genetic associations with toxi ...... tor therapy for breast cancer.
@en
type
label
Genetic associations with toxi ...... tor therapy for breast cancer.
@en
prefLabel
Genetic associations with toxi ...... tor therapy for breast cancer.
@en
P2093
P2860
P50
P1476
Genetic associations with toxi ...... tor therapy for breast cancer.
@en
P2093
Anna M Storniolo
Anne T Nguyen
Christina Gersch
Daniel F Hayes
James M Rae
Jessica Dantzer
N Lynn Henry
Santosh Philips
Steffi Oesterreich
P2860
P2888
P304
P356
10.1007/S10549-013-2504-3
P407
P577
2013-04-02T00:00:00Z